Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
1994-11-29
|
| pubmed:abstractText |
In an attempt to develop the most effective cytokine gene therapy, we transfected mouse interleukin(IL)-2, mouse IL-4, and human IL-6 cDNAs into mouse melanoma cells, B16F10. Transfection with IL-4 cDNA decreased the tumorigenicity of B16F10 most strongly. We investigated whether gene therapy with IL-4-transfected B16F10 cells was possible. Flow-cytometric analysis showed that major histocompatibility complex class I and II expression in B16F10 and IL-4-cDNA-transfected B16F10 (B16F10-IL4) cells did not differ. Doubling times of B16F10 and B16F10-IL4 were 20.1 and 21.1 h respectively. The growth of B16F10 cells was retarded if C57BL/6 mice were inoculated with B16F10-IL4 at the contralateral sides. When 5 x 10(5) B16F10 cells were transplanted subcutaneously into the flanks of C57BL/6 mice, they all developed a tumor mass, whereas no tumor masses formed in those transplanted with B16F10-IL4 cells within 60 days. No nude, severe combined immunodeficient or beige mice were able to reject parental B16F10 or B16F10-IL4 cells, although, B16F10-IL4 tumor growth in all these immunodeficient mice was slower than that of B16F10. Therefore, we concluded that T and natural killer cells are necessary for rejection of B16F10-IL4 tumor cells.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0171-5216
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
120
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
631-5
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7962038-Animals,
pubmed-meshheading:7962038-Cell Division,
pubmed-meshheading:7962038-DNA, Complementary,
pubmed-meshheading:7962038-Evaluation Studies as Topic,
pubmed-meshheading:7962038-Female,
pubmed-meshheading:7962038-Gene Therapy,
pubmed-meshheading:7962038-Immunologic Deficiency Syndromes,
pubmed-meshheading:7962038-Interleukin-2,
pubmed-meshheading:7962038-Interleukin-4,
pubmed-meshheading:7962038-Interleukin-6,
pubmed-meshheading:7962038-Male,
pubmed-meshheading:7962038-Melanoma, Experimental,
pubmed-meshheading:7962038-Mice,
pubmed-meshheading:7962038-Mice, Inbred BALB C,
pubmed-meshheading:7962038-Mice, Inbred C57BL,
pubmed-meshheading:7962038-Mice, Nude,
pubmed-meshheading:7962038-Mice, SCID,
pubmed-meshheading:7962038-Neoplasm Transplantation,
pubmed-meshheading:7962038-Transfection,
pubmed-meshheading:7962038-Tumor Cells, Cultured,
pubmed-meshheading:7962038-Vaccination
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant.
|
| pubmed:affiliation |
Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|